{"filing":{"accession_number":"0001193125-26-337069","cik":"0001422142","ticker":"WHWK","company_name":"Whitehawk Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"whwk-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-20260806.htm"},"events":[{"id":25581,"run_id":23217,"accession_number":"0001193125-26-337069","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The press release includes condensed consolidated balance sheets and statements of operations showing cash position of $190.0 million, R\u0026D expenses of $12.9 million, and net loss of $16.6 million for the quarter. The disclosure is material as it provides investors with the company's financial performance and cash runway guidance into 2H 2028.","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26455,"accession_number":"0001193125-26-337069","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The press release includes condensed consolidated balance sheets and statements of operations showing cash position of $190.0 million, R\u0026D expenses of $12.9 million, and net loss of $16.6 million for the quarter. The disclosure is material as it provides investors with the company's financial performance and cash runway guidance into 2H 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:57.775395+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26455,"accession_number":"0001193125-26-337069","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The press release includes condensed consolidated balance sheets and statements of operations showing cash position of $190.0 million, R\u0026D expenses of $12.9 million, and net loss of $16.6 million for the quarter. The disclosure is material as it provides investors with the company's financial performance and cash runway guidance into 2H 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:57.775395+00:00","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-08-06"}]}